Impact of pathogen reduction methods on immunological properties of the COVID-19 convalescent plasma.

Kostin AI, Lundgren MN, Bulanov AY, Ladygina EA, Chirkova KS, Gintsburg AL, Logunov DY, Dolzhikova IV, Shcheblyakov DV, Borovkova NV, Godkov MA, Bazhenov AI, Shustov VV, Bogdanova AS, Kamalova AR, Ganchin VV, Dombrovskiy EA, Volkov SE, Drozdova NE, Petrikov SS

Vox Sang 116 (6) 665-672 [2021-07-00; online 2021-03-18]

COVID-19 convalescent plasma is an experimental treatment against SARS-CoV-2. The aim of this study is to assess the impact of different pathogen reduction methods on the levels and virus neutralizing activity of the specific antibodies against SARS-CoV2 in convalescent plasma. A total of 140 plasma doses collected by plasmapheresis from COVID-19 convalescent donors were subjected to pathogen reduction by three methods: methylene blue (M)/visible light, riboflavin (R)/UVB and amotosalen (A)/UVA. To conduct a paired comparison, individual plasma doses were divided into 2 samples that were subjected to one of these methods. The titres of SARS-CoV2 neutralizing antibodies (NtAbs) and levels of specific immunoglobulins to RBD, S- and N-proteins of SARS-CoV-2 were measured before and after pathogen reduction. The methods reduced NtAbs titres differently: among units with the initial titre 80 or above, 81% of units remained unchanged and 19% decreased by one step after methylene blue; 60% were unchanged and 40% decreased by one step after amotosalen; after riboflavin 43% were unchanged and 50% (7%, respectively) had a one-step (two-step, respectively) decrease. Paired two-sample comparisons (M vs. A, M vs. R and A vs. R) revealed that the largest statistically significant decrease in quantity and activity of the specific antibodies resulted from the riboflavin treatment. Pathogen reduction with methylene blue or with amotosalen provides the greater likelihood of preserving the immunological properties of the COVID-19 convalescent plasma compared to riboflavin.

Category: Health

Type: Journal article

PubMed 33734455

DOI 10.1111/vox.13056

Crossref 10.1111/vox.13056

pmc: PMC8250394

Publications 7.1.2